Inventor · disambiguated record
Christoph Steeneck
Also filed as: STEENECK CHRISTOPH
23 granted patents·13 pending applications·165 citations·filing 2005–2021
94Inventor score
Files withPHENEX PHARMACEUTICALS AG7ALANTOS PHARM HOLDING5JANSSEN PHARMACEUTICA NV5GILEAD SCIENCES INC4ALANTOS PHARMACEUTICALS INC3
Top patents by PatentIndex Score
36 records- 0197US9539244B2FXR (NR1H4) binding and activity modulating compoundsGILEAD SCIENCES INC·Filed 2015·Granted Jan 10, 2017·28 cites·17 claims
- 0295US9820979B2FXR (NR1H4) binding and activity modulating compoundsGILEAD SCIENCES INC·Filed 2016·Granted Nov 21, 2017·16 cites·6 claims
- 0394US10485795B2FXR (NR1H4) binding and activity modulating compoundsGILEAD SCIENCES INC·Filed 2019·Granted Nov 26, 2019·10 cites·18 claims
- 0494US9139539B2FXR (NR1H4) binding and activity modulating compoundsKINZEL OLAF·Filed 2012·Granted Sep 22, 2015·42 cites·10 claims
- 0593US10220027B2FXR (NR1H4) binding and activity modulating compoundsGILEAD SCIENCES INC·Filed 2017·Granted Mar 5, 2019·10 cites·16 claims
- 0693US8952042B2FXR (NR1H4) binding and activity modulating compoundsKREMOSER CLAUS·Filed 2010·Granted Feb 10, 2015·43 cites·9 claims
- 0778US10981908B2Aryl hydrocarbon receptor (AHR) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Granted Apr 20, 2021·1 cites·18 claims
- 0877US9850236B2Trifluoromethyl alcohols as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Dec 26, 2017·2 cites·43 claims
- 0976US8076330B2Dipeptidyl peptidase-IV inhibitorsKROTH HEIKO·Filed 2011·Granted Dec 13, 2011·4 cites·24 claims
- 1072US8835441B2Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2011·Granted Sep 16, 2014·3 cites·10 claims
- 1171US9458104B2Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγPHENEX PHARMACEUTICALS AG·Filed 2013·Granted Oct 4, 2016·2 cites·23 claims
- 1270US7713966B2Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Granted May 11, 2010·1 cites·12 claims
- 1369US7795245B2Heterobicyclic metalloprotease inhibitorsATLANTOS PHARMACEUTICALS HOLDI·Filed 2007·Granted Sep 14, 2010·2 cites·15 claims
- 1466US9815851B2Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseasesPHENEX PHARMACEUTICALS AG·Filed 2012·Granted Nov 14, 2017·1 cites·22 claims
- 1561US2009312312A1Heterobicyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 1660US2010009961A1Dipeptidyl peptidase-iv inhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 1756US2007155738A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 1854US10150762B2Trifluoromethyl alcohols as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Dec 11, 2018·0 cites·15 claims
- 1953US2023108408A1Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)PHENEX PHARMACEUTICALS AG·Filed 2021·Application pending·0 cites
- 2052US2008161300A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Application pending·0 cites
- 2150US10080744B2Thiazoles as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Sep 25, 2018·0 cites·26 claims
- 2248US11376241B2Aryl hydrocarbon receptor (AhR) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Granted Jul 5, 2022·0 cites·14 claims
- 2345US2006293345A1Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2006·Application pending·0 cites
- 2444US9861618B2Thiazoles as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Jan 9, 2018·0 cites·8 claims
- 2543US2007155739A1Substituted bis-amide metalloprotease inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2643US2008021024A1Metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Application pending·0 cites
- 2742US10301272B2Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]PHENEX PHARMACEUTICALS AG·Filed 2013·Granted May 28, 2019·0 cites·30 claims
- 2841US2008176870A1Heterobicyclic metalloprotease inhibitorsNOLTE BERT·Filed 2007·Application pending·0 cites
- 2939US2006173183A1Multicyclic bis-amide MMP inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 3039US2020031805A1Aryl hydrocarbon receptor (ahr) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
- 3137US8946446B2Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseasesSTEENECK CHRISTOPH·Filed 2012·Granted Feb 3, 2015·0 cites·16 claims
- 3236US9845319B2Amide substituted thiazoles as modulators of RORytJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Dec 19, 2017·0 cites·24 claims
- 3333US11078168B2Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenasePHENEX DISCOVERY VERWALTUNGS GMBH·Filed 2017·Granted Aug 3, 2021·0 cites·17 claims
- 3432US8940722B2Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseaseKINZEL OLAF·Filed 2011·Granted Jan 27, 2015·0 cites·10 claims
- 3530US2021122757A1Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenasePHENEX DISCOVERY VERWALTUNGS GMBH·Filed 2019·Application pending·0 cites
- 3628US2020352931A1Oxalamides as modulators of indoleamine 2,3-dioxygenasePHENEX DISCOVERY VERWALTUNGS GMBH·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Steeneck files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →